Bristol-Myers Squibb (NYSE:BMY – Get Rating) EVP Rupert Vessey sold 45,910 shares of Bristol-Myers Squibb stock in a transaction dated Monday, November 7th. The shares were sold at an average price of $78.88, for a total value of $3,621,380.80. Following the completion of the sale, the executive vice president now directly owns 57,079 shares in the company, valued at approximately $4,502,391.52. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
Bristol-Myers Squibb Trading Down 0.5 %
Shares of NYSE:BMY opened at $79.38 on Friday. Bristol-Myers Squibb has a 12-month low of $53.22 and a 12-month high of $81.17. The stock has a market cap of $168.77 billion, a PE ratio of 25.86, a P/E/G ratio of 1.87 and a beta of 0.40. The business has a 50 day moving average of $72.33 and a 200-day moving average of $73.99. The company has a quick ratio of 1.31, a current ratio of 1.42 and a debt-to-equity ratio of 1.13.
Bristol-Myers Squibb (NYSE:BMY – Get Rating) last issued its quarterly earnings data on Wednesday, October 26th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.83 by $0.16. Bristol-Myers Squibb had a return on equity of 50.30% and a net margin of 14.29%. The company had revenue of $11.22 billion during the quarter, compared to analysts’ expectations of $11.18 billion. During the same quarter in the previous year, the company posted $2.00 earnings per share. The business’s revenue was down 3.5% on a year-over-year basis. As a group, equities research analysts forecast that Bristol-Myers Squibb will post 7.6 earnings per share for the current year.
Bristol-Myers Squibb Dividend Announcement
Analyst Ratings Changes
A number of analysts recently issued reports on BMY shares. UBS Group lifted their target price on Bristol-Myers Squibb to $73.00 and gave the company an “outperform” rating in a research report on Wednesday, July 27th. JPMorgan Chase & Co. lifted their target price on Bristol-Myers Squibb from $80.00 to $85.00 in a research report on Thursday, July 28th. Guggenheim downgraded Bristol-Myers Squibb from a “buy” rating to a “neutral” rating in a research report on Monday, October 10th. Morgan Stanley lowered their target price on Bristol-Myers Squibb from $61.00 to $60.00 and set an “underweight” rating on the stock in a research report on Thursday, October 27th. Finally, StockNews.com assumed coverage on Bristol-Myers Squibb in a research report on Wednesday, October 12th. They issued a “strong-buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $79.08.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the company. Spectrum Management Group LLC raised its position in Bristol-Myers Squibb by 113.1% during the first quarter. Spectrum Management Group LLC now owns 341 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 181 shares in the last quarter. Schubert & Co increased its holdings in shares of Bristol-Myers Squibb by 119.1% during the second quarter. Schubert & Co now owns 333 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 181 shares in the last quarter. Castle Wealth Management LLC acquired a new position in shares of Bristol-Myers Squibb during the second quarter worth $26,000. Nauset Wealth Management. LLC acquired a new position in shares of Bristol-Myers Squibb during the first quarter worth $27,000. Finally, Evolution Advisers Inc. acquired a new position in shares of Bristol-Myers Squibb during the first quarter worth $29,000. 76.54% of the stock is currently owned by institutional investors and hedge funds.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.
- Get a free copy of the StockNews.com research report on Bristol-Myers Squibb (BMY)
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don’t Want to Get Stuck On
- Vision Hydrogen, Now Vision Energy, Puts Hopes In Stock Split
- Hanesbrands May be Signaling a Bad Week for Retail Stocks
- Coupang Stock And Why You Should Care
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.